SynthesisBMC cancer2026

Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy in breast cancer: a systematic review and meta-analysis with focus on triple-negative subtype and immune-related adverse events.

Aisaide Aikelaimu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.